AACR Immuno-Oncology Conference (AACR IO)
Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
February 18-21, 2026
JW Marriott Los Angeles L.A. Live
Los Angeles, California
Clinical Trial and Late-Breaking Abstract Submission Deadline: Tuesday, January 20, 2026, 1 p.m. ET (opens Monday, January 5, 2026)
Scientific Committee chairs
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, New York
Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
Make plans to join us again in Los Angeles for AACR Immuno-Oncology Conference (AACR IO—encompassing the very best of basic, translational, and clinical research in immunology, inflammation, and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies. The inaugural AACR IO 2025 program attracted over 600 basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. The unique format included a mix of keynote lectures, major symposia, spotlight sessions, educational sessions, special sessions, and poster sessions with exhibits.
Scientific Committee
Rafi Ahmed, Emory University, Atlanta, Georgia
Sebastian Amigorena, Institut Curie, Paris, France
Lisa H. Butterfield, Merck & Co., Kenilworth, New Jersey
Lieping Chen, Yale University, New Haven, Connecticut
Luca Gattinoni, Leibniz Institute for Immunotherapy, Regensburg, Germany
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
Susan M. Kaech, Salk Institute Cancer Center, La Jolla, California
Lewis L. Lanier, University of California, San Francisco, California
Alexander Marson, University of California, San Francisco, California
Ira Mellman, Parker Institute for Cancer Immunotherapy, San Francisco, California
Avery D. Posey, University of Pennsylvania, Philadelphia, Pennsylvania
Michel Sadelain, Columbia University, New York, New York
Catherine Sautes-Fridman, INSERM U1138, Beine Nauroy, France
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Ton Schumacher, Netherlands Cancer Institute, Amsterdam, Netherlands
Marcel R.M. van den Brink, City of Hope National Medical Center, Duarte, California
Robert Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania
Catherine Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
Clinical Trials and Late-Breaking Abstracts Committee
Renier J. Brentjens, Roswell Park Comprehensive Cancer Center, Roswell Park, New York
Tina Cascone, The University of Texas MD Anderson Cancer Center, Houston
Jason A. Chesney, University of Louisville, Louisville, Kentucky
George Coukos, University of Lausanne, Lausanne, Switzerland
Charles G. Drake, Janssen Pharmaceuticals, Spring House, Pennsylvania
John B.A.G. Haanen, Netherlands Cancer Institute, Amsterdam, Netherlands
Patrick Hwu, Moffitt Cancer Center, Tampa, Florida
Harriet Kluger, Yale School of Medicine, New Haven, Connecticut
Quyhn-Thu Le, Stanford Cancer Institute, Stanford, California
Ignacio Melero, Clínica Universidad de Navarra, Pamplona, Spain
Adekunle Odunsi, University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Katayoun Rezvani, The University of Texas MD Anderson Cancer Center, Houston, Texas
Pedro J. Romero, Novigenix SA and University of Lausanne, Lausanne, Switzerland
Please Note: All presentations at this event represent the opinions of the presenter and do not represent the position or the opinion of the AACR or its members.
